Marcus Hompesch

3.2k total citations
82 papers, 2.3k citations indexed

About

Marcus Hompesch is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Marcus Hompesch has authored 82 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Endocrinology, Diabetes and Metabolism, 41 papers in Surgery and 18 papers in Molecular Biology. Recurrent topics in Marcus Hompesch's work include Diabetes Management and Research (47 papers), Diabetes Treatment and Management (47 papers) and Pancreatic function and diabetes (35 papers). Marcus Hompesch is often cited by papers focused on Diabetes Management and Research (47 papers), Diabetes Treatment and Management (47 papers) and Pancreatic function and diabetes (35 papers). Marcus Hompesch collaborates with scholars based in United States, Germany and South Korea. Marcus Hompesch's co-authors include Linda Morrow, Lutz Heinemann, Andrew J. Krentz, Ken Fujioka, Douglas B. Muchmore, Daniel E. Vaughn, Sherwyn Schwartz, Donna Skee, An Vandebosch and Damayanthi Devineni and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Marcus Hompesch

76 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marcus Hompesch United States	27	1.6k	966	627	241	227	82	2.3k
Francesca Pizzolo Italy	29	937 0.6×	780 0.8×	613 1.0×	111 0.5×	181 0.8×	83	2.5k
Roy Eldor Israel	24	1.8k 1.1×	1.1k 1.2×	1.1k 1.7×	210 0.9×	391 1.7×	70	2.9k
Stanley S. Schwartz United States	21	1.4k 0.9×	573 0.6×	671 1.1×	184 0.8×	257 1.1×	64	2.3k
Nanwei Tong China	25	1.1k 0.7×	407 0.4×	779 1.2×	144 0.6×	128 0.6×	124	2.4k
Carolina Solis‐Herrera United States	18	1.3k 0.8×	828 0.9×	791 1.3×	158 0.7×	126 0.6×	38	1.7k
Valdis Pīrāgs Latvia	22	1.0k 0.6×	527 0.5×	877 1.4×	94 0.4×	164 0.7×	86	2.1k
Maria Luiza Caramori United States	16	852 0.5×	368 0.4×	555 0.9×	137 0.6×	239 1.1×	32	2.7k
Baptist Gallwitz Germany	20	1.9k 1.2×	708 0.7×	812 1.3×	251 1.0×	143 0.6×	87	2.4k
Marcel H.A. Muskiet Netherlands	28	2.5k 1.5×	1.1k 1.2×	870 1.4×	442 1.8×	132 0.6×	66	3.5k
Gary Herman United States	27	1.8k 1.1×	758 0.8×	905 1.4×	423 1.8×	50 0.2×	58	2.6k

Countries citing papers authored by Marcus Hompesch

Since Specialization

Citations

This map shows the geographic impact of Marcus Hompesch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus Hompesch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus Hompesch more than expected).

Fields of papers citing papers by Marcus Hompesch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcus Hompesch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus Hompesch. The network helps show where Marcus Hompesch may publish in the future.

Co-authorship network of co-authors of Marcus Hompesch

This figure shows the co-authorship network connecting the top 25 collaborators of Marcus Hompesch. A scholar is included among the top collaborators of Marcus Hompesch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus Hompesch. Marcus Hompesch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Younossi, Zobair M., Homie Razavi, Michael S. Sherman, et al.. (2025). Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics. 61(9). 1467–1478. 8 indexed citations

Casu, Anna, Fanchao Yi, Tumpa Dutta, et al.. (2025). A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes. Diabetes. 74(7). 1262–1272. 1 indexed citations

Lapuerta, Pablo, et al.. (2024). A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin. Clinical Pharmacology & Therapeutics. 115(6). 1383–1390. 1 indexed citations

Ratziu, Vlad, Marcus Hompesch, Janani Iyer, et al.. (2023). Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. Journal of Hepatology. 80(2). 335–351. 47 indexed citations

Shin, Won‐Jung, et al.. (2023). Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long‐acting glucagon analogue HM15136 in overweight and obese patients with co‐morbidities. Diabetes Obesity and Metabolism. 25(9). 2723–2733. 2 indexed citations

Baek, Seung Jae, et al.. (2019). 982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects. Diabetes. 68(Supplement_1). 7 indexed citations

Powell, David R., Brian Zambrowicz, Linda Morrow, et al.. (2019). OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption. Journal of the Endocrine Society. 3(Supplement_1). 2 indexed citations

Krentz, Andrew J. & Marcus Hompesch. (2016). Glucose: Archetypal Biomarker in Diabetes Diagnosis, Clinical Management and Research. Biomarkers in Medicine. 10(11). 1153–1166. 16 indexed citations

Heise, Tim, Stefan Korsatko, Leszek Nosek, et al.. (2015). Steady state is reached within 2–3 days of once‐daily administration of degludec, a basal insulin with an ultralong duration of action. Journal of Diabetes. 8(1). 132–138. 35 indexed citations

10.

Hompesch, Marcus, et al.. (2014). Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics. 36(4). 507–515. 14 indexed citations

11.

Devineni, Damayanthi, Linda Morrow, Marcus Hompesch, et al.. (2012). Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obesity and Metabolism. 14(6). 539–545. 192 indexed citations

12.

Morrow, Linda, Douglas B. Muchmore, Elizabeth Ludington, Daniel E. Vaughn, & Marcus Hompesch. (2011). Reduction in Intrasubject Variability in the Pharmacokinetic Response to Insulin After Subcutaneous Co-Administration with Recombinant Human Hyaluronidase in Healthy Volunteers. Diabetes Technology & Therapeutics. 13(10). 1039–1045. 14 indexed citations

13.

Morrow, Linda, et al.. (2011). Continuous Glucose Monitoring Using a Novel Glucose/Galactose Binding Protein: Results of a 12-Hour Feasibility Study with the Becton Dickinson Glucose/Galactose Binding Protein Sensor. Diabetes Technology & Therapeutics. 13(3). 309–317. 17 indexed citations

14.

Kauh, Eunkyung, Lori Mixson, Sudha S. Shankar, et al.. (2011). Short‐term metabolic effects of prednisone administration in healthy subjects. Diabetes Obesity and Metabolism. 13(11). 1001–1007. 17 indexed citations

15.

Hompesch, Marcus, Douglas B. Muchmore, Linda Morrow, Elizabeth Ludington, & Daniel E. Vaughn. (2011). Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase. Diabetes Technology & Therapeutics. 14(3). 218–224. 19 indexed citations

16.

Ocheltree, Scott M., et al.. (2010). Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. European Journal of Endocrinology. 163(2). 217–223. 20 indexed citations

17.

Morrow, Linda, et al.. (2010). Co‐administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obesity and Metabolism. 13(1). 75–80. 34 indexed citations

18.

Hompesch, Marcus, Alexa P. Kollmeier, Klaus Rave, et al.. (2009). Glycemic Exposure Is Affected Favorably by Inhaled Human Insulin (Exubera) as Compared with Subcutaneous Insulin Glargine (Lantus) in Patients with Type 2 Diabetes. Diabetes Technology & Therapeutics. 11(5). 307–313. 4 indexed citations

19.

Nauck, M., et al.. (2006). Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes. Experimental and Clinical Endocrinology & Diabetes. 114(8). 417–423. 111 indexed citations

20.

Kapitza, Christoph, Marcus Hompesch, B. SCHARLING, & Tim Heise. (2004). Intrasubject Variability of Inhaled Insulin in Type 1 Diabetes: A Comparison with Subcutaneous Insulin. Diabetes Technology & Therapeutics. 6(4). 466–472. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact